Currently, the incidence of Parkinson's disease (PD) is on the rise. More and more evidences suggest that mitochondrial dysfunction plays a crucial role in the etiology of PD, and dysfunction of mitochondrial complex I (MCI) is one of the most critical factors leading to mitochondrial dysfunction. On one hand, MCI dysfunction stimulates dopaminergic neurons to produce reactive oxygen species (ROS). On the other hand, MCI dysfunction decreases dopaminergic neuron viability and reduces ATP production. All these outcomes promote the pathological progression of PD. This review summarizes research progress on the role of MCI in the pathogenesis of PD, as well as PD treatment strategies based on MCI.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The role of mA modification during macrophage metabolic reprogramming in human diseases and animal models.
Front Immunol
March 2025
Department of Laboratory Medicine, Jiangsu Province Engineering Research Center for Precise Diagnosis and Treatment of Inflammatory Diseases, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Macrophage metabolic reprogramming refers to the process by which macrophages adjust their physiological pathways to meet survival and functional demands in different immune microenvironments. This involves a range of metabolic pathways, including glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation, fatty acid oxidation, and cholesterol transport. By modulating the expression and activity of key enzymes and molecules within these pathways, macrophages can make the transition between pro- and anti-inflammatory phenotypes, thereby linking metabolic reprogramming to inflammatory responses and the progression of several diseases, such as atherosclerosis, inflammatory bowel disease (IBD), and acute lung injury (ALI).
View Article and Find Full Text PDFThe changes of NLRs family members in the brain of AD mouse model and AD patients.
Front Immunol
March 2025
College of Medicine, Yanbian University, Yanji, China.
Introduction: Alzheimer's disease (AD), a prevalent neurodegenerative disease, is primarily characterized by progressive neuron loss and memory impairment. NOD-like receptors (NLRs) are crucial for immune regulation and maintaining cellular homeostasis. Recently, NLRs have been identified as important contributors to neuroinflammation, thus presenting a potential approach for reducing inflammation and slowing AD progression.
View Article and Find Full Text PDFUnveiling SSR4: a promising biomarker in esophageal squamous cell carcinoma.
Front Immunol
March 2025
Department of Digestive Endoscopy, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Background: Esophageal squamous cell carcinoma (ESCC) represents a frequent cancer with a poor prognosis. Altered glucose metabolism contributes factor to ESCC progression. In our previous study, signal sequence receptor subunit delta (SSR4) was included in an ESCC prognostic model; however, the mechanisms underlying SSR4 implication in ESCC remain ambiguous.
View Article and Find Full Text PDFA comprehensive prognostic and immunological implications of Gremlin 1 in lung adenocarcinoma.
Front Immunol
March 2025
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Article Synopsis
- GREM1 is linked to tumor progression and poor prognosis in lung adenocarcinoma (LUAD), which is a common and aggressive form of lung cancer.
- The study uses various analyses, including gene expression data and survival analysis, to demonstrate that higher levels of GREM1 are associated with worse patient outcomes and influence the immune microenvironment.
- Experimental results show that GREM1 promotes LUAD cell growth and movement, highlighting its potential as a target for future therapies in personalized cancer treatment.
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg.
Front Immunol
March 2025
Department of Dermatology, Gesundheit Nord Klinikverbund Bremen, Bremen, Germany.
Background: Although systemic therapies have improved considerably over the last decade, up to 50% of patients with metastatic melanoma still die due to disease progression. Oncological treatment at the end-of-life phase is challenging. The aim of this study was to investigate the frequency and type of systemic therapy received by melanoma patients in their end-of-life phase.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!